LIT goes hunting for lithium in “elephant country”

|

Published 27-APR-2016 13:12 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Lithium Australia (ASX:LIT) is aiming to become a key player in both of WA’s lithium hotspots – gaining a license to explore in the famous Greenbushes area.

It told its investors today that it had been granted exploration permits from the WA government to starting looking in an area which currently produces roughly 40% of the world’s lithium needs.

Talison Australia currently produces from the Greenbushes area, but LIT has applied for and received the right to look around in permits right next door to the producing land.

It said that it would start softly with technical work in order to build up a better geotechnical suite of information on the permits.

While the area has been explored in the past, this has been centred on tin and tantalum – with LIT hoping more modern exploration techniques will expose deeper-lying lithium.

Managing director Adrian Griffin said the granting of the licenses would allow it to establish a foothold in two of WA’s lthium hotspots.

“Greenbushes is certainly elephant country when it comes to lithium,” he said.

“Recent activity in the area rivals that of the Pilgangoora hot spot and we are one of the few companies firmly established in both locations.”

Yesterday it told its shareholders that it is moving forward with a plan to set up a processing hub in the Pilbara region – enlisting the help of Venus Metals Corporation (ASX:VMC) to do so.

LIT is currently applying for a WA government grant to help set up the centre, and LIT is hoping to bring a co-investor on board to help make the decision easier for the government.

In the spirit of closer ties with VMC, LIT elected to take part in VMC’s recent $1 million private placement – and the pair is also working on a desktop study on the region as well.

LIT has been on an upstream spree in recent times, having taken an option to explore in the Northern Territory in a region it has labelled a Greenbushes lookalike – and more recently having kicked off an exploration campaign in Mexico.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X